Damora Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -10 | -9 | -8 | |
EBITDA | -3,146 | -3,412 | -2,591 | |
EBIT | -3,156 | -3,421 | -2,599 | |
Net Income | -200,736 | -3,133 | -3,437 | -2,533 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | 566 | -2,616 | -2,237 | -2,439 |
Cash | 7,606 | 10,211 | 11,939 | |
Basic Shares | 1,327 | 1,322 | 1,322 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -181 | -830 | -490 | |
EBITDA | -16,716 | -35,627 | -60,717 | |
EBIT | -16,897 | -36,457 | -61,207 | |
Net Income | -209,839 | -21,439 | -38,349 | -61,624 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -18,623 | -36,911 | -43,128 | |
Cash | 257,624 | 14,175 | 21,465 | 32,786 |
Basic Shares | 1,597 | 1,157 | 1,062 | 1,016 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $2.30 |
2025-09-30 | -$2.36 |
2025-06-30 | -$2.59 |
2025-03-31 | -$1.91 |
